View ValuationClínica Baviera 将来の成長Future 基準チェック /06現在、 Clínica Bavieraの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare 収益成長20.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to €24.30Down from €29.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of €18.10. Stock is down 11% over the past year. The company is forecast to post earnings per share of €1.80 for next year compared to €1.68 last year.すべての更新を表示Recent updatesDeclared Dividend • Apr 27Dividend of €1.27 announcedShareholders will receive a dividend of €1.27. Ex-date: 10th June 2026 Payment date: 12th June 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 21% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Apr 25Clínica Baviera, S.A., Annual General Meeting, May 27, 2026Clínica Baviera, S.A., Annual General Meeting, May 27, 2026. Location: paseo de la castellana 20, madrid., SpainReported Earnings • Mar 05Full year 2025 earnings released: EPS: €2.58 (vs €2.51 in FY 2024)Full year 2025 results: EPS: €2.58 (up from €2.51 in FY 2024). Revenue: €304.9m (up 15% from FY 2024). Net income: €42.1m (up 4.6% from FY 2024). Profit margin: 14% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.Buy Or Sell Opportunity • Feb 09Now 23% undervaluedOver the last 90 days, the stock has risen 32% to €53.00. The fair value is estimated to be €68.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 12%.New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (4.4% average weekly change).分析記事 • Jan 24We Think Clínica Baviera (BME:CBAV) Can Manage Its Debt With EaseSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Dec 01Third quarter 2025 earnings released: EPS: €0.34 (vs €0.29 in 3Q 2024)Third quarter 2025 results: EPS: €0.34 (up from €0.29 in 3Q 2024). Revenue: €65.3m (up 17% from 3Q 2024). Net income: €5.49m (up 19% from 3Q 2024). Profit margin: 8.4% (up from 8.2% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.Buy Or Sell Opportunity • Nov 27Now 20% overvaluedOver the last 90 days, the stock has fallen 2.4% to €44.80. The fair value is estimated to be €37.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%.Buy Or Sell Opportunity • Sep 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €45.00. The fair value is estimated to be €37.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%.Buy Or Sell Opportunity • Aug 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to €45.00. The fair value is estimated to be €37.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%.Buy Or Sell Opportunity • Aug 05Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €45.20. The fair value is estimated to be €37.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 12%.Reported Earnings • Jul 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €75.9m (up 14% from 2Q 2024). Net income: €9.45m (down 14% from 2Q 2024). Profit margin: 13% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (4.5% average weekly change).Buy Or Sell Opportunity • Jun 27Now 23% undervaluedOver the last 90 days, the stock has risen 11% to €39.90. The fair value is estimated to be €51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 13%.Upcoming Dividend • Jun 04Upcoming dividend of €1.27 per shareEligible shareholders must have bought the stock before 11 June 2025. Payment date: 13 June 2025. Payout ratio is a comfortable 64% and this is well supported by cash flows. Trailing yield: 3.7%. Lower than top quartile of Spanish dividend payers (4.9%). Higher than average of industry peers (2.3%).Buy Or Sell Opportunity • May 28Now 21% undervaluedOver the last 90 days, the stock has risen 16% to €38.70. The fair value is estimated to be €48.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.お知らせ • Apr 25Clínica Baviera, S.A., Annual General Meeting, May 27, 2025Clínica Baviera, S.A., Annual General Meeting, May 27, 2025. Location: paseo de la castellana 20, madrid Spain分析記事 • Apr 10A Piece Of The Puzzle Missing From Clínica Baviera, S.A.'s (BME:CBAV) Share PriceWith a price-to-earnings (or "P/E") ratio of 13x Clínica Baviera, S.A. ( BME:CBAV ) may be sending bullish signals at...お知らせ • Apr 04Clínica Baviera, S.A. has filed a Follow-on Equity Offering.Clínica Baviera, S.A. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,304,606 Transaction Features: Subsequent Direct ListingReported Earnings • Nov 26Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €56.0m (up 20% from 3Q 2023). Net income: €4.59m (down 23% from 3Q 2023). Profit margin: 8.2% (down from 13% in 3Q 2023). The decrease in margin was driven by higher expenses.New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.4% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Valuation Update With 7 Day Price Move • Nov 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €32.70, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Healthcare industry in Europe. Total returns to shareholders of 103% over the past three years.分析記事 • Oct 18Clínica Baviera (BME:CBAV) Is Achieving High Returns On Its CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...New Risk • Sep 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.2% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.分析記事 • Sep 19Clínica Baviera (BME:CBAV) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Jul 28First half 2024 earnings released: EPS: €1.44 (vs €1.29 in 1H 2023)First half 2024 results: EPS: €1.44 (up from €1.29 in 1H 2023). Revenue: €133.0m (up 14% from 1H 2023). Net income: €23.4m (up 12% from 1H 2023). Profit margin: 18% (in line with 1H 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jul 13Market Cool On Clínica Baviera, S.A.'s (BME:CBAV) EarningsClínica Baviera, S.A.'s ( BME:CBAV ) price-to-earnings (or "P/E") ratio of 14.5x might make it look like a buy right...Upcoming Dividend • Jul 09Upcoming dividend of €1.27 per shareEligible shareholders must have bought the stock before 16 July 2024. Payment date: 18 July 2024. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 5.4%. Lower than top quartile of Spanish dividend payers (5.5%). Higher than average of industry peers (2.2%).Reported Earnings • Mar 04Full year 2023 earnings releasedFull year 2023 results: Revenue: €224.9m (up 13% from FY 2022). Net income: €36.7m (up 24% from FY 2022). Profit margin: 16% (up from 15% in FY 2022). The increase in margin was driven by higher revenue.分析記事 • Mar 01Clínica Baviera (BME:CBAV) Might Become A Compounding MachineTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Reported Earnings • Nov 27Third quarter 2023 earnings releasedThird quarter 2023 results: EPS: €0.36. Revenue: €46.9m (up 12% from 3Q 2022). Net income: €5.93m (up 18% from 3Q 2022). Profit margin: 13% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 27First half 2023 earnings releasedFirst half 2023 results: EPS: €1.29. Revenue: €116.7m (up 13% from 1H 2022). Net income: €21.0m (up 9.6% from 1H 2022). Profit margin: 18% (in line with 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 26% per year.Upcoming Dividend • May 24Upcoming dividend of €0.65 per share at 6.9% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 6.9%. Within top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (2.4%).Reported Earnings • Mar 02Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: €1.81 (up from €1.68 in FY 2021). Revenue: €198.4m (up 14% from FY 2021). Net income: €29.5m (up 7.8% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.5%. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 07Upcoming dividend of €0.41 per shareEligible shareholders must have bought the stock before 14 December 2022. Payment date: 16 December 2022. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.6%. Lower than top quartile of Spanish dividend payers (5.8%). Higher than average of industry peers (3.0%).分析記事 • Nov 20Clínica Baviera's (BME:CBAV) Dividend Will Be €0.405The board of Clínica Baviera, S.A. ( BME:CBAV ) has announced that it will pay a dividend of €0.405 per share on the...Price Target Changed • Nov 16Price target decreased to €24.30Down from €29.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of €18.10. Stock is down 11% over the past year. The company is forecast to post earnings per share of €1.80 for next year compared to €1.68 last year.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Isabel Navarro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Jul 28Second quarter 2022 earnings released: EPS: €0.49 (vs €0.51 in 2Q 2021)Second quarter 2022 results: EPS: €0.49 (down from €0.51 in 2Q 2021). Revenue: €50.5m (up 11% from 2Q 2021). Net income: €8.04m (down 2.5% from 2Q 2021). Profit margin: 16% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 2.1%, compared to a 6.2% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 18Upcoming dividend of €0.43 per shareEligible shareholders must have bought the stock before 25 May 2022. Payment date: 27 May 2022. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 4.4%. Lower than top quartile of Spanish dividend payers (5.5%). Higher than average of industry peers (2.4%).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Isabel Navarro was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 15Full year 2021 earnings released: EPS: €1.68 (vs €0.85 in FY 2020)Full year 2021 results: EPS: €1.68 (up from €0.85 in FY 2020). Revenue: €173.2m (up 41% from FY 2020). Net income: €27.4m (up 97% from FY 2020). Profit margin: 16% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.9%, compared to a 6.8% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 03Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €1.68 (up from €0.85 in FY 2020). Revenue: €173.2m (up 41% from FY 2020). Net income: €27.4m (up 97% from FY 2020). Profit margin: 16% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.分析記事 • Jan 20Investors Shouldn't Overlook Clínica Baviera's (BME:CBAV) Impressive Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...Upcoming Dividend • Dec 14Upcoming dividend of €0.41 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 23 December 2021. Payout ratio is a comfortable 49% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of Spanish dividend payers (5.2%). Higher than average of industry peers (2.0%).分析記事 • Sep 15These 4 Measures Indicate That Clínica Baviera (BME:CBAV) Is Using Debt SafelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Valuation Update With 7 Day Price Move • Sep 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €20.60, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 26x in the Healthcare industry in Europe. Total returns to shareholders of 66% over the past three years.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improved over the past weekAfter last week's 38% share price gain to €20.00, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 31x in the Healthcare industry in Europe. Total returns to shareholders of 52% over the past three years.Upcoming Dividend • May 19Inaugural dividend of €0.45 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 28 May 2021. The company last paid an ordinary dividend in April 2019. The average dividend yield among industry peers is 1.7%.Valuation Update With 7 Day Price Move • May 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to €15.10, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 29x in the Healthcare industry in Europe. Total returns to shareholders of 22% over the past three years.分析記事 • Apr 12Investors Shouldn't Overlook The Favourable Returns On Capital At Clínica Baviera (BME:CBAV)If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • Mar 21Clínica Baviera (BME:CBAV) Seems To Use Debt Rather SparinglyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Feb 22Clínica Baviera, S.A.'s (BME:CBAV) Stock Is Going Strong: Is the Market Following Fundamentals?Most readers would already be aware that Clínica Baviera's (BME:CBAV) stock increased significantly by 28% over the...分析記事 • Jan 30Shareholders Of Clínica Baviera (BME:CBAV) Must Be Happy With Their 177% Total ReturnIt might be of some concern to shareholders to see the Clínica Baviera, S.A. ( BME:CBAV ) share price down 16% in the...分析記事 • Jan 09Here's What To Make Of Clínica Baviera's (BME:CBAV) Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to €13.60, the stock is trading at a trailing P/E ratio of 25.4x, up from the previous P/E ratio of 21.7x. This compares to an average P/E of 26x in the Healthcare industry in Europe. Total returns to shareholders over the past three years are 67%.分析記事 • Dec 19Here's Why We Think Clínica Baviera's (BME:CBAV) Statutory Earnings Might Be ConservativeIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. Having...Is New 90 Day High Low • Dec 16New 90-day high: €12.00The company is up 36% from its price of €8.80 on 17 September 2020. The Spanish market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period.分析記事 • Nov 28Clínica Baviera (BME:CBAV) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Nov 16New 90-day high: €9.40The company is up 4.0% from its price of €9.00 on 18 August 2020. The Spanish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 14New 90-day low: €8.30The company is down 13% from its price of €9.55 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day low: €8.75The company is down 10.0% from its price of €9.70 on 26 June 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 4.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Clínica Baviera は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BME:CBAV - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025305424777N/A9/30/2025297404672N/A6/30/2025289394267N/A3/31/2025280414267N/A12/31/2024266403663N/A9/30/2024252373663N/A6/30/2024243383967N/A3/31/2024234373561N/A12/31/2023227363558N/A9/30/2023217323657N/A6/30/2023212313654N/A3/31/2023205303854N/A12/31/2022198303953N/A9/30/2022193303950N/A6/30/2022189304051N/A3/31/2022184314253N/A12/31/2021173273647N/A9/30/2021165283546N/A6/30/2021160273848N/A3/31/2021134202937N/A12/31/2020123142431N/A9/30/2020117122127N/A6/30/202011291521N/A3/31/2020124111523N/A12/31/2019124131625N/A9/30/201911912N/A23N/A6/30/201911512N/A20N/A3/31/201911012N/AN/AN/A12/31/201810912N/A17N/A9/30/201810711N/AN/AN/A6/30/201810612N/A18N/A3/31/201810411N/AN/AN/A12/31/201710010N/A16N/A9/30/2017978N/AN/AN/A6/30/2017948N/A13N/A3/31/2017928N/AN/AN/A12/31/2016928N/A14N/A9/30/2016929N/AN/AN/A6/30/2016918N/A14N/A3/31/2016886N/AN/AN/A12/31/2015865N/A11N/A9/30/2015844N/AN/AN/A6/30/2015834N/A8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CBAVの予測収益成長が 貯蓄率 ( 2.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CBAVの収益がSpanish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CBAVの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CBAVの収益がSpanish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CBAVの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CBAVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 21:30終値2026/05/29 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Clínica Baviera, S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関León Izuzquiza LenzeBanco de Sabadell. S.A.Marta DiazBanco de Sabadell. S.A.Bosco Muguiro EulateBanco Santander2 その他のアナリストを表示
Price Target Changed • Nov 16Price target decreased to €24.30Down from €29.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of €18.10. Stock is down 11% over the past year. The company is forecast to post earnings per share of €1.80 for next year compared to €1.68 last year.
Declared Dividend • Apr 27Dividend of €1.27 announcedShareholders will receive a dividend of €1.27. Ex-date: 10th June 2026 Payment date: 12th June 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 21% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 25Clínica Baviera, S.A., Annual General Meeting, May 27, 2026Clínica Baviera, S.A., Annual General Meeting, May 27, 2026. Location: paseo de la castellana 20, madrid., Spain
Reported Earnings • Mar 05Full year 2025 earnings released: EPS: €2.58 (vs €2.51 in FY 2024)Full year 2025 results: EPS: €2.58 (up from €2.51 in FY 2024). Revenue: €304.9m (up 15% from FY 2024). Net income: €42.1m (up 4.6% from FY 2024). Profit margin: 14% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
Buy Or Sell Opportunity • Feb 09Now 23% undervaluedOver the last 90 days, the stock has risen 32% to €53.00. The fair value is estimated to be €68.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 12%.
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (4.4% average weekly change).
分析記事 • Jan 24We Think Clínica Baviera (BME:CBAV) Can Manage Its Debt With EaseSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Dec 01Third quarter 2025 earnings released: EPS: €0.34 (vs €0.29 in 3Q 2024)Third quarter 2025 results: EPS: €0.34 (up from €0.29 in 3Q 2024). Revenue: €65.3m (up 17% from 3Q 2024). Net income: €5.49m (up 19% from 3Q 2024). Profit margin: 8.4% (up from 8.2% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.
Buy Or Sell Opportunity • Nov 27Now 20% overvaluedOver the last 90 days, the stock has fallen 2.4% to €44.80. The fair value is estimated to be €37.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%.
Buy Or Sell Opportunity • Sep 08Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €45.00. The fair value is estimated to be €37.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%.
Buy Or Sell Opportunity • Aug 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to €45.00. The fair value is estimated to be €37.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%.
Buy Or Sell Opportunity • Aug 05Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €45.20. The fair value is estimated to be €37.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 12%.
Reported Earnings • Jul 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €75.9m (up 14% from 2Q 2024). Net income: €9.45m (down 14% from 2Q 2024). Profit margin: 13% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (4.5% average weekly change).
Buy Or Sell Opportunity • Jun 27Now 23% undervaluedOver the last 90 days, the stock has risen 11% to €39.90. The fair value is estimated to be €51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 13%.
Upcoming Dividend • Jun 04Upcoming dividend of €1.27 per shareEligible shareholders must have bought the stock before 11 June 2025. Payment date: 13 June 2025. Payout ratio is a comfortable 64% and this is well supported by cash flows. Trailing yield: 3.7%. Lower than top quartile of Spanish dividend payers (4.9%). Higher than average of industry peers (2.3%).
Buy Or Sell Opportunity • May 28Now 21% undervaluedOver the last 90 days, the stock has risen 16% to €38.70. The fair value is estimated to be €48.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%.
お知らせ • Apr 25Clínica Baviera, S.A., Annual General Meeting, May 27, 2025Clínica Baviera, S.A., Annual General Meeting, May 27, 2025. Location: paseo de la castellana 20, madrid Spain
分析記事 • Apr 10A Piece Of The Puzzle Missing From Clínica Baviera, S.A.'s (BME:CBAV) Share PriceWith a price-to-earnings (or "P/E") ratio of 13x Clínica Baviera, S.A. ( BME:CBAV ) may be sending bullish signals at...
お知らせ • Apr 04Clínica Baviera, S.A. has filed a Follow-on Equity Offering.Clínica Baviera, S.A. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,304,606 Transaction Features: Subsequent Direct Listing
Reported Earnings • Nov 26Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €56.0m (up 20% from 3Q 2023). Net income: €4.59m (down 23% from 3Q 2023). Profit margin: 8.2% (down from 13% in 3Q 2023). The decrease in margin was driven by higher expenses.
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.4% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Valuation Update With 7 Day Price Move • Nov 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €32.70, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Healthcare industry in Europe. Total returns to shareholders of 103% over the past three years.
分析記事 • Oct 18Clínica Baviera (BME:CBAV) Is Achieving High Returns On Its CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
New Risk • Sep 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.2% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
分析記事 • Sep 19Clínica Baviera (BME:CBAV) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Jul 28First half 2024 earnings released: EPS: €1.44 (vs €1.29 in 1H 2023)First half 2024 results: EPS: €1.44 (up from €1.29 in 1H 2023). Revenue: €133.0m (up 14% from 1H 2023). Net income: €23.4m (up 12% from 1H 2023). Profit margin: 18% (in line with 1H 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jul 13Market Cool On Clínica Baviera, S.A.'s (BME:CBAV) EarningsClínica Baviera, S.A.'s ( BME:CBAV ) price-to-earnings (or "P/E") ratio of 14.5x might make it look like a buy right...
Upcoming Dividend • Jul 09Upcoming dividend of €1.27 per shareEligible shareholders must have bought the stock before 16 July 2024. Payment date: 18 July 2024. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 5.4%. Lower than top quartile of Spanish dividend payers (5.5%). Higher than average of industry peers (2.2%).
Reported Earnings • Mar 04Full year 2023 earnings releasedFull year 2023 results: Revenue: €224.9m (up 13% from FY 2022). Net income: €36.7m (up 24% from FY 2022). Profit margin: 16% (up from 15% in FY 2022). The increase in margin was driven by higher revenue.
分析記事 • Mar 01Clínica Baviera (BME:CBAV) Might Become A Compounding MachineTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Reported Earnings • Nov 27Third quarter 2023 earnings releasedThird quarter 2023 results: EPS: €0.36. Revenue: €46.9m (up 12% from 3Q 2022). Net income: €5.93m (up 18% from 3Q 2022). Profit margin: 13% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 27First half 2023 earnings releasedFirst half 2023 results: EPS: €1.29. Revenue: €116.7m (up 13% from 1H 2022). Net income: €21.0m (up 9.6% from 1H 2022). Profit margin: 18% (in line with 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 26% per year.
Upcoming Dividend • May 24Upcoming dividend of €0.65 per share at 6.9% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 6.9%. Within top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (2.4%).
Reported Earnings • Mar 02Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: €1.81 (up from €1.68 in FY 2021). Revenue: €198.4m (up 14% from FY 2021). Net income: €29.5m (up 7.8% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.5%. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 07Upcoming dividend of €0.41 per shareEligible shareholders must have bought the stock before 14 December 2022. Payment date: 16 December 2022. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.6%. Lower than top quartile of Spanish dividend payers (5.8%). Higher than average of industry peers (3.0%).
分析記事 • Nov 20Clínica Baviera's (BME:CBAV) Dividend Will Be €0.405The board of Clínica Baviera, S.A. ( BME:CBAV ) has announced that it will pay a dividend of €0.405 per share on the...
Price Target Changed • Nov 16Price target decreased to €24.30Down from €29.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of €18.10. Stock is down 11% over the past year. The company is forecast to post earnings per share of €1.80 for next year compared to €1.68 last year.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Isabel Navarro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Jul 28Second quarter 2022 earnings released: EPS: €0.49 (vs €0.51 in 2Q 2021)Second quarter 2022 results: EPS: €0.49 (down from €0.51 in 2Q 2021). Revenue: €50.5m (up 11% from 2Q 2021). Net income: €8.04m (down 2.5% from 2Q 2021). Profit margin: 16% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 2.1%, compared to a 6.2% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 18Upcoming dividend of €0.43 per shareEligible shareholders must have bought the stock before 25 May 2022. Payment date: 27 May 2022. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 4.4%. Lower than top quartile of Spanish dividend payers (5.5%). Higher than average of industry peers (2.4%).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Isabel Navarro was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 15Full year 2021 earnings released: EPS: €1.68 (vs €0.85 in FY 2020)Full year 2021 results: EPS: €1.68 (up from €0.85 in FY 2020). Revenue: €173.2m (up 41% from FY 2020). Net income: €27.4m (up 97% from FY 2020). Profit margin: 16% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.9%, compared to a 6.8% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 03Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €1.68 (up from €0.85 in FY 2020). Revenue: €173.2m (up 41% from FY 2020). Net income: €27.4m (up 97% from FY 2020). Profit margin: 16% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
分析記事 • Jan 20Investors Shouldn't Overlook Clínica Baviera's (BME:CBAV) Impressive Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
Upcoming Dividend • Dec 14Upcoming dividend of €0.41 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 23 December 2021. Payout ratio is a comfortable 49% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of Spanish dividend payers (5.2%). Higher than average of industry peers (2.0%).
分析記事 • Sep 15These 4 Measures Indicate That Clínica Baviera (BME:CBAV) Is Using Debt SafelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Valuation Update With 7 Day Price Move • Sep 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €20.60, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 26x in the Healthcare industry in Europe. Total returns to shareholders of 66% over the past three years.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improved over the past weekAfter last week's 38% share price gain to €20.00, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 31x in the Healthcare industry in Europe. Total returns to shareholders of 52% over the past three years.
Upcoming Dividend • May 19Inaugural dividend of €0.45 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 28 May 2021. The company last paid an ordinary dividend in April 2019. The average dividend yield among industry peers is 1.7%.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to €15.10, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 29x in the Healthcare industry in Europe. Total returns to shareholders of 22% over the past three years.
分析記事 • Apr 12Investors Shouldn't Overlook The Favourable Returns On Capital At Clínica Baviera (BME:CBAV)If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
分析記事 • Mar 21Clínica Baviera (BME:CBAV) Seems To Use Debt Rather SparinglyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Feb 22Clínica Baviera, S.A.'s (BME:CBAV) Stock Is Going Strong: Is the Market Following Fundamentals?Most readers would already be aware that Clínica Baviera's (BME:CBAV) stock increased significantly by 28% over the...
分析記事 • Jan 30Shareholders Of Clínica Baviera (BME:CBAV) Must Be Happy With Their 177% Total ReturnIt might be of some concern to shareholders to see the Clínica Baviera, S.A. ( BME:CBAV ) share price down 16% in the...
分析記事 • Jan 09Here's What To Make Of Clínica Baviera's (BME:CBAV) Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to €13.60, the stock is trading at a trailing P/E ratio of 25.4x, up from the previous P/E ratio of 21.7x. This compares to an average P/E of 26x in the Healthcare industry in Europe. Total returns to shareholders over the past three years are 67%.
分析記事 • Dec 19Here's Why We Think Clínica Baviera's (BME:CBAV) Statutory Earnings Might Be ConservativeIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. Having...
Is New 90 Day High Low • Dec 16New 90-day high: €12.00The company is up 36% from its price of €8.80 on 17 September 2020. The Spanish market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period.
分析記事 • Nov 28Clínica Baviera (BME:CBAV) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Nov 16New 90-day high: €9.40The company is up 4.0% from its price of €9.00 on 18 August 2020. The Spanish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 14New 90-day low: €8.30The company is down 13% from its price of €9.55 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day low: €8.75The company is down 10.0% from its price of €9.70 on 26 June 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 4.0% over the same period.